This week's biggest % winners & losers: Apr 26 - 30, 2021 (wk 17)

This week's biggest % gainers/losers The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: CRY (29.57 +28.96%), CSLT (1.9 +23.38%)
• Industrials: TBI (28.52 +23.76%)
• Consumer Discretionary: UXIN (2.95 +37.21%), FLWS (31.17 +29.96%), AAN (30.92 +19.94%), CROX (99.95 +18.78%), MHO (69.69 +16.9%), NDLS (12.24 +16.46%), OSTK (81.46 +16.1%)
• Information Technology: PFPT (172.25 +30.71%), EVRI (17.68 +17.48%)
• Financials: DB (14.02 +18.01%)
• Energy: LPI (40.96 +21.72%), GPRE (29.76 +19.14%), NOG (14.55 +19.07%), LBRT (11.88 +17.16%), TELL (2.22 +16.14%)

This week's top % losers

• Healthcare: CARA (13.02 -50.59%)
• Materials: FSM (6.00 -22.18%), CDE (8.14 -15.47%), PQG (14.12 -15.28%), RFP (13.55 -13.95%)
• Industrials: ENPH (139.87 -16.23%)
• Information Technology: FORM (39.05 -20.25%), SGH (46.16 -16.42%), RBBN (6.78 -15.73%), CRUS (73.58 -15.41%), PI (47.07 -15.01%), AMKR (20.25 -14.99%), IIVI (66.96 -14.01%), AZPN (129.97 -13.85%), CREE (99.41 -13.38%), CASA (7.86 -13.05%), FSLR (77.42 -12.58%)
• Financials: GHL (15.40 -17.34%)
• Energy: ARLP (5.47 -16.36%)

Cara Therapeutics (CARA) : Korsuva fails for the treatment in atopic dermatitis (AD) patients

  

 

 

 

 

 

 

 

Cara Therapeutics announces topline results from its KARE Phase 2 dose-ranging clinical trial of Oral KORSUVA for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis patients

Study did not meet Primary Endpoint of worst-itch NRS change from baseline at week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population.

Study achieved Primary Endpoint of worst-itch NRS change and Secondary Endpoint of 4-point responder analysis in pre-specified analyses of mild-to-moderate AD patients (64% of ITT patient population).

Statistically significant improvement in 4-point responder analysis in mild-to-moderate (BSA <10%) AD patients with 32% of KORSUVA-treated patients achieving a > 4-point reduction vs. 19% in placebo group (p=0.03).

KORSUVA was well tolerated at all dose levels.

-=Cara Therapeutics (CARA) : disappointing Korsuva data for kidney disease

• Reports mixed topline results from its Phase 2 dose-ranging trial of Oral KORSUVA (CR845/difelikefalin) for the treatment of pruritus in patients with stage III-V (moderate-to-severe) chronic kidney disease; miss on secondary endpoints overshadows primary endpoint

Cara Therapeutics announced positive topline results from its Phase 2 dose-ranging trial of Oral KORSUVA for the treatment of pruritus in patients with stage III-V (moderate-to-severe) chronic kidney disease

Patients treated with the 1 mg tablet strength of Oral KORSUVA achieved the primary endpoint of statistically significant reduction in weekly mean of the daily WI-NRS scores vs. placebo after the 12-week treatment period (-4.4 KORSUVA vs. -3.3 placebo, p=0.018). The treatment effect was statistically significant after two weeks of treatment and sustained through the 12-week treatment period.

The proportion of patients on 1 mg tablet strength achieving a 3 point or greater improvement from baseline in the weekly mean of the daily WI-NRS score at week 12 was 72% vs. 58% for placebo but did not achieve statistical significance.

=Cara Therapeutics (CARA) : 'positive' top-line data

Cara Therapeutics announces 'positive' top-line data from the adaptive Phase 2/3 trial of I.V. CR845 in patients undergoing abdominal surgeries  

At the 1.0 mcg/kg dose, I.V. CR845 demonstrated statistically significant reductions in pain intensity compared to placebo at all pre-specified post-operative periods of 0-6 hours (p=0.001); 0-12 hours (p=0.004); 0-18 hours (p=0.013); and 0-24 hours (p=0.032). Additionally, I.V. CR845 treatment resulted in statistically significant reductions in the incidence of post-operative nausea and vomiting over the 24-hour period post-surgery for both 0.5 and 1.0 mcg/kg doses .

• The full results of this trial will be presented at a future scientific or medical conference.

=Cara Therapeutics Inc (CARA) reported earnings on Thur 3 Aug 2017 (a/h)

• Cara Therapeutics is developing its CR701 as an alternative to opioids

STAMFORD, Conn. (AP) _ Cara Therapeutics Inc. (CARA) on Thursday reported a loss of $9.3 million in its second quarter.

The Stamford, Connecticut-based company said it had a loss of 29 cents per share.

The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 62 cents per share.

Cara shares have increased 43 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $13.30, more than doubling in the last 12 months.

=Cara Therapeutics (CARA) announces top-line results from phase 2B trial

Cara Therapeutics announces top-line results from a Phase 2b trial of an oral tablet formulation of CR845 in patients with osteoarthritis of the knee or hip; Statistically significant 39 percent reduction in mean joint pain score in hip patients at eight weeks with 5.0 mg dose :

• Patients with OA of the hip maintained on the 5.0 mg dose to the end of the eight-week treatment period exhibited a statistically significant 39 percent reduction in mean joint pain score (p=0.043 vs. placebo); all patients (OA of the knee or hip) maintained on the 5.0 mg dose to the end of the eight-week treatment period exhibited a 35 percent reduction in mean joint pain score (p=0.111 vs. placebo).
• Patients maintained on the 1.0 mg and 2.5 mg tablet strengths did not exhibit significant reductions in mean joint pain scores compared to placebo.
• For patients maintained on the 5.0 mg dose, there was a statistically significant increase in the proportion of patients whose OA was "very much improved" or "much improved" as indicated by Patient Global Assessment score in both the total patient group (p <0.005 vs. placebo) and in patients with primary OA of the hip (p<0.006 vs. placebo).
• The reduction in pain score in the 5.0 mg dose group in hip patients was accompanied by a reduction in mean rescue medication of 41 percent at week eight versus placebo.
• An overall improvement of 62 percent from baseline in WOMAC scores was observed over the eight-week treatment period for the 5.0 mg dose group in hip patients.
• All tablet strengths were generally well tolerated with no drug-related serious adverse events (SAEs). For the 5.0 mg dose, the most common adverse events reported at the >5 percent incidence level were dry mouth (six percent) and constipation (12 percent). Importantly, there were no clinically significant changes in serum sodium levels observed during the eight-week treatment period for any dose group.

"We believe that the present trial of oral CR845 has highlighted the potential of a peripherally acting kappa agonist to provide clinical benefit in a chronic pain population and we're pleased that statistical significance was achieved for the 5.0 mg dose in patients with OA of the hip"

Cara Therapeutics (CARA) reported earnings on Thur 3 Nov 2016 (a/h)

** charts before earnings **

  

** charts after earnings **

  

Cara Therapeutics beats by $0.05  :

• Reports Q3 (Sep) loss of $0.42 per share, $0.05 better than the Capital IQ Consensus of ($0.47).
• The Company did not recognize any revenue during the third quarter of 2016. During the third quarter of 2015, total revenue recognized was $2.4 million, including $1.7 million of license and milestone fees revenue and $730,000 of collaborative revenue, comprising revenue which was earned upon achievement of defined milestones under the license agreements with Maruishi Pharmaceutical Company Ltd. and Chong Kun Dang Pharmaceutical Company, as well as revenue that had been deferred upon entry into the license agreement with Maruishi.
• Based on timing expectations and projected costs for current clinical development plans, Cara expects that its existing cash and cash equivalents and available-for-sale marketable securities as of September 30, 2016 will be sufficient for the Company to fund its operating expenses and capital expenditure requirements through the end of the first quarter of 2018, without giving effect to any potential milestone payments under existing collaborations.